|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
Thomas Lingelbach
|
|
gptkbp:collaboratedWith
|
gptkb:Pfizer
Bavarian Nordic
|
|
gptkbp:country
|
gptkb:France
|
|
gptkbp:developedBy
|
VLA2001
DUKORAL
IXIARO
VLA15
VLA1553
|
|
gptkbp:focusesOn
|
infectious diseases
|
|
gptkbp:founded
|
2013
|
|
gptkbp:fundedBy
|
gptkb:Parliament_of_the_United_Kingdom
gptkb:CEPI
|
|
gptkbp:headquartersLocation
|
gptkb:Saint-Herblain,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valneva
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
FR0004056851
|
|
gptkbp:listedOn
|
gptkb:Nasdaq
gptkb:Euronext_Paris
|
|
gptkbp:numberOfEmployees
|
~700 (2023)
|
|
gptkbp:officeLocation
|
gptkb:Saint-Herblain,_France
|
|
gptkbp:product
|
gptkb:Cholera_vaccine
gptkb:Japanese_encephalitis_vaccine
vaccine
Chikungunya vaccine (in development)
Lyme disease vaccine (in development)
|
|
gptkbp:specializesIn
|
vaccines
|
|
gptkbp:subsidiary
|
Valneva Austria GmbH
Valneva Sweden AB
|
|
gptkbp:tradedOn
|
VALN (Nasdaq)
VLA (Euronext Paris)
|
|
gptkbp:website
|
https://valneva.com
|
|
gptkbp:bfsParent
|
gptkb:Dukoral
gptkb:EU_Vaccines_Strategy
gptkb:Vaccines_Europe
gptkb:Chikungunya_vaccine_(under_development)
|
|
gptkbp:bfsLayer
|
7
|